Division of Cardiology, Department of Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy.
Division of Cardiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Echocardiography. 2021 Apr;38(4):518-524. doi: 10.1111/echo.15015. Epub 2021 Mar 5.
The prevalence of left atrial thrombi in patients scheduled for electrical cardioversion (ECV) of atrial fibrillation (AF) remains unknown in contemporary real-life practice.
Patients scheduled for ECV underwent transesophageal echocardiography (TEE) regardless of AF duration and type of anticoagulant. Of 277 consecutive patients (65% men, mean age 71 ± 10 years, CHA DS -VASc 3.1 ± 1.4), 92 were on direct oral anticoagulants (DOACs) and 99 on antivitamin K (AVK) oral agents for at least 3 weeks before and 4 after ECV. Eighty-five patients with paroxysmal AF on low-molecular-weight heparin were also considered. Real time three-dimensional TEE detected left atrial appendage (LAA) thrombus in 7% of patients, without significant difference among three groups (P = .334). Anticoagulation was ineffective in eight patients on AVK oral agents, two of them had thrombus. Eight patients assumed incorrectly DOACs, four of them had thrombus. Among the 175 patients on effective anticoagulation, five showed thrombus, three on AVK oral agents, and two on DOACs (P = .716). Effective anticoagulation was associated with reduced risk of thrombosis (OR: 0.16, 95%CI: 0.06-0.45, P = .001). In patients with correct anticoagulation, predictors of thrombus were CHA DS VASc (for each point of increment OR: 1.97, 95%CI: 1.08-3.61, P = .029), low left ventricular ejection fraction (OR: 0.92, 95%CI: 0.86-0.99, P = .026), and degree of spontaneous echo-contrast (for each point increase OR: 10, 95%CI: 2-39, P < .0001).
Patients with AF, on effective anticoagulation, had a prevalence of thrombus not negligible regardless of type of anticoagulant. TEE is prudent before ECV and mandatory if unsuccessful anticoagulation is proved or suspected.
在接受电复律(ECV)治疗心房颤动(AF)的患者中,左心房血栓的发生率在当代真实实践中尚不清楚。
无论 AF 持续时间和抗凝类型如何,所有计划接受 ECV 的患者均接受经食管超声心动图(TEE)检查。在 277 例连续患者中(65%为男性,平均年龄 71 ± 10 岁,CHA2DS2-VASc 评分为 3.1 ± 1.4),92 例患者接受直接口服抗凝剂(DOAC)治疗,99 例患者接受维生素 K 拮抗剂(AVK)口服药物治疗,至少在 ECV 前 3 周和后 4 周开始抗凝。还考虑了 85 例接受低分子肝素抗凝的阵发性 AF 患者。实时三维 TEE 检测到 7%的患者存在左心耳(LAA)血栓,三组之间无显著差异(P =.334)。8 例接受 AVK 口服药物治疗的患者抗凝无效,其中 2 例有血栓。8 例患者错误地服用了 DOAC,其中 4 例有血栓。在 175 例接受有效抗凝治疗的患者中,有 5 例出现血栓,其中 3 例在 AVK 口服药物治疗组,2 例在 DOAC 治疗组(P =.716)。有效的抗凝治疗与血栓形成风险降低相关(OR:0.16,95%CI:0.06-0.45,P =.001)。在接受正确抗凝治疗的患者中,血栓形成的预测因素包括 CHA2DS2-VASc 评分(每增加 1 分,OR:1.97,95%CI:1.08-3.61,P =.029)、左心室射血分数降低(OR:0.92,95%CI:0.86-0.99,P =.026)和自发回声对比程度(每增加 1 分,OR:10,95%CI:2-39,P <.0001)。
接受 AF 治疗、接受有效抗凝治疗的患者,无论抗凝药物类型如何,其血栓形成的发生率均不容忽视。在 ECV 之前进行 TEE 检查是谨慎的,如果证实或怀疑抗凝治疗无效,则必须进行 TEE 检查。